Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

NCT05508906 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer
ER-positive Breast Cancer
HER2-negative Breast Cancer
Breast Cancer
Locally Advanced Breast Cancer

Interventions

DRUG: Palazestrant
DRUG: Ribociclib
DRUG: Alpelisib
DRUG: Everolimus
DRUG: Atirmociclib

Sponsor

Olema Pharmaceuticals, Inc.

Collaborators

[object Object]
[object Object]